Find a Doctor or Practice Location

Are you a referring physician?
I am searching for a
Reset Form
Jakub Svoboda, MD

Jakub Svoboda, MD Physician

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Languages spoken:

  • Czech

Dr. Svoboda is employed by Penn Medicine.

About Dr. Jakub Svoboda

Recognized by America's Top Doctors for 2017

Recognized in Philadelphia magazine's May 2018 Top Docs issue

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties


  • Hematology
  • Medical Oncology

Programs & Centers:

Board Certification:

  • Medical Oncology, 2006

Clinical Expertise:

  • Cutaneous T-Cell Lymphoma
  • Hodgkin Lymphoma
  • Lymphoma
  • Non-Hodgkin Lymphoma
  • Stem Cell Transplant

Description of Clinical Expertise

I have expertise in treating all subtypes of lymphomas and CLL/SLL.

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Yale University
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania


American College of Physicians, National American Society of Clinical Oncology, National American Society of Hematology, National Mid-Atlantic Lymphoma Research Consortium, Local North American Hodgkin Lymphoma Consortium, National

Hospital Affiliation

Dr. Svoboda is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.


Description of Research Expertise:

My research interests focus on improving outcomes in patients with lymphomas. I am interested in the use of novel agents and immune based therapies which have the potential to be more effective and less toxic than conventional treatments. I have served as the principal investigator on several trials including multicenter investigator initiated trial using brentuximab (immunoconjugate) in combination with chemotherapy as frontline treatment for CD30+ B-cell lymphomas. I have also conducted a pilot trial using CAR T cells in patients in relapsed/refractory Hodgkin lymphoma. My current clinical projects include a trial using novel combination of targeted agents in relapsed/refractory Hodgkin lymphoma and am working on development of new strategies for cell/immune-based therapies. I am also interested in studying molecular signatures and other factors that will allow us to better tailor therapies for our patients. Some of the collaborative work with our translational scientists may allow us to find new therapeutic targets.

Selected Publications:

Stephen J. Schuster, M.D., Jakub Svoboda, M.D., Elise A. Chong, M.D., Sunita D. Nasta, M.D., Anthony R. Mato, M.D., Özlem Anak, M.D., Jennifer L. Brogdon, Ph.D., Iulian Pruteanu-Malinici, Ph.D., Vijay Bhoj, M.D., Ph.D., Daniel Landsburg, M.D., Mariusz Wasik, M.D., Bruce L. Levine, Ph.D., Simon F. Lacey, Ph.D., Jan J. Melenhorst, Ph.D., David L. Porter, M.D., and Carl H. June, M.D.: Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas New England Journal of Medicine 377 : 2545-2554,2017.

Jakub Svoboda, Susan R Rheingold, Saar I Gill, Stephan A Grupp, Simon F Lacey, J Joseph Melenhorst, Irina Kulikovskaya, Brandon Loudon, Naseem Kerr, Katherine T Marcucci, Kim-Marie Shea, Aliza Schmidt, Lester Lledo, Amy Marshall, Anthony R Mato, Sunita Dwivedy Nasta, Daniel J Landsburg, Matthew R Youngman, Bruce L Levine, David L Porter, Carl H June, Stephen J Schuster: Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory/Relapsed Hodgkin Lymphoma (HL) Blood 130 : 653-653,2017.

Jakub Svoboda, Daniel J Landsburg, Sunita Dwivedy Nasta, Stefan Klaus Barta, Nadia Khan, Henry C Fung, Carlyn Rose Tan, Joanne Filicko-O'Hara, Sameh Gaballa, Lauren Elizabeth Strelec, Sarah J Nagle, Steven M Bair, Sheryl Mitnick, Terease S Waite, Rachel Lynn Sargent, Agata M Bogusz, Ziver Sahin, Anthony R Mato, Stephen J Schuster: Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial Blood 130 (Suppl 1): 191-191,2017.

Nirav N Shah, Aniko Szabo, Scott F Huntington, Narendranath Epperla, Nishitha Reddy, Siddhartha Ganguly, Julie Vose, Cynthia Obiozor, Fahad Faruqi, Alexandra E Kovach, Luciano J Costa, Ana C Xaiver, Ryan Okal, Abraham S Kanate, Nilanjan Ghosh, Mohamed A Kharfan‐Dabaja, Lauren Strelec, Mehdi Hamadani, Timothy S Fenske, Oscar Calzada, Jonathon B Cohen, Julio Chavez, Jakub Svoboda: R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis British Journal of Haematology : 2017.

Ruan, J., Martin, P., Shah, B., Schuster, S.J., Smith, S.M., Furman, R.R., Christos, P., Rodriguez, A., Svoboda, J., Lewis, J., Katz, O., Coleman, M., and Leonard, J.P.: Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma. New England Journal of Medicine 373 (19): 1835-44,2015.

Huntington Scott F, Svoboda Jakub, Doshi Jalpa A: Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission. Journal of Clinical Oncology 33 (13): 1467-74,2015.

SM Bair, L Strelec, SJ Nagle, SD Nasta, DJ Landsburg, AR Mato, AW Loren, SJ Schuster, EA Stadtmauer, J Svoboda: Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis American Journal of Hematology : 2017.

Anthony R. Mato, Chadi Nabhan, Paul M. Barr, Chaitra S. Ujjani, Brian T. Hill, Nicole Lamanna, Alan P. Skarbnik, Christina Howlett, Jeffrey J. Pu, Alison R. Sehgal, Lauren E. Strelec, Alexandra Vandegrift, Danielle M. Fitzpatrick, Clive S. Zent, Tatyana Feldman, Andre Goy, David F. Claxton, Spencer Henick Bachow, Gurbakhash Kaur, Jakub Svoboda, Sunita Dwivedy Nasta, David Porter, Daniel J. Landsburg, Stephen J. Schuster, Bruce D. Cheson, Pavel Kiselev and Andrew M. Evens: Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience Blood : 2016.

AR Mato, BT Hill, N Lamanna, PM Barr, CS Ujjani, DM Brander, C Howlett, AP Skarbnik, BD Cheson, CS Zent, JJ Pu, P Kiselev, K Foon, J Lenhart, S Henick Bachow, AM Winter, A-L Cruz, DF Claxton, A Goy, C Daniel, K Isaac, KH Kennard, C Timlin, M Fanning, L Gashonia, M Yacur, J Svoboda, SJ Schuster, C Nabhan: Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients Annals of Oncology 28 (5): 1050-1056,2017.

Nagle, SJ, Woo, K, Schuster, SJ, Nasta, SD, Stadtmauer, E, Mick, R, Svoboda, J: Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era American Journal of Hematology 88 (10): 890-894,2013.

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-158
3400 Civic Center Boulevard

Philadelphia, PA 19104
Phone: (215) 614-1846
Patient appointments: 800-789-7366 (PENN)

Related Links